Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab (Lukexin) in rheumatoid arthritis patients in disease activity target with postmenopausal osteoporosis
ChiCTR2400090526Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of leflunomide in postmenopausal osteoporosis (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Rate of change in bone mineral density at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
leflunomide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on ChiCTR2400090526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090526.